To date, these trials have proven their value, all things being equal, no reason for it not to the same for Phase 3.
Opthea won't know which patient got what dise or sham. However they do need to monitor in full the safety of the Phase 3 program, so they will be the very first to know of any adverse effects.
To date, these trials have proven their value, all things being...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.030(6.12%) |
Mkt cap ! $328.0M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 52.0¢ | 48.3¢ | $273.6K | 546.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47051 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 16084 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
51.8¢ |
Change
0.030 ( 4.86 %) |
||||
| Open | High | Low | Volume | ||
| 48.5¢ | 52.0¢ | 48.5¢ | 102223 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| OPT (ASX) Chart |